Kennedy Eugene P. 4

4 · NEWLINK GENETICS CORP · Filed Aug 2, 2019

Insider Transaction Report

Form 4

Period: 2019-07-31

NEWLINK GENETICS CORP(NLNK)

Kennedy Eugene P.

Chief Medical Officer

Transactions

Award
Stock Option (Right to Buy)
2019-07-31+4,297→ 4,297 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (4,297 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+9,167→ 9,167 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (9,167 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−37,500→ 0 total
Exercise: $8.90From: 2017-12-13Exp: 2027-11-12→ Common Stock (37,500 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+7,813→ 7,813 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (7,813 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−110,000→ 0 total
Exercise: $7.85→ Common Stock (110,000 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+15,889→ 15,889 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (15,889 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+4,582→ 4,582 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (4,582 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+6,641→ 6,641 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (6,641 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+6,875→ 6,875 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (6,875 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+2,445→ 2,445 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (2,445 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+6,875→ 6,875 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (6,875 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+4,587→ 4,587 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (4,587 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+4,582→ 4,582 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (4,582 underlying)

Footnotes (5)

[F1]On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share.
[F2]The option vests as to 50% on the first anniversary of grant date and the remaining 50% on the second anniversary of grant date.
[F3]The option vests as to 50% on the second anniversary of grant date and the remaining 50% on the third anniversary of grant date.
[F4]The option provided that 50% of the option grant would vest in a series of 48 successive equal monthly installments beginning on April 9, 2018 and the remaining 50% would vest upon specified performance objectives, in each case, provided that as the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.
[F5]Unless otherwise disclosed, the option expires ten years after the date of grant.

Documents

1 file

4
wf-form4_156478562322802.xmlPrimary
FORM 4